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WHAT IS THE CURRENT HyPE 
AROUND VITAMIN D? 
During the last decade, there has been an explosion of interest in the ‘sunshine vitamin’ as scientists 
started to suggest that the effect of vitamin D in the 
body extends far beyond its role in healthy bones. At the 
same time, the sales of vitamin D supplements skyrock-
eted in developed countries, as indicated by a statement 
from Jamieson Laboratories, Canada’s largest supple-
ment maker: “The nutrient is flying off pharmacy shelves 
in amounts that are astonishing players in the nutritional 
supplement business” and “vitamin D sales eclipsed those 
of vitamin C for the first time ever … capping a year of 
huge growth for the product”.1 Similar ly, the number of 
laboratory tests for vitamin D has increased exponen-
tially, from approximately 4 000 samples per month in 
2004 to 50 000 samples per month in 2008 in just one 
laboratory.2 Vitamin D testing has been described as the 
fastest-growing test in medical laboratories in the USA 
and other developed nations across the globe due to 
an unprecedented demand. The cause of this increased 
demand for vitamin D supplements and testing is the 
press coverage of reports of a high prevalence of vita-
min D deficiency, as well as the steady flow of scientific 
publications that link vitamin D deficiency with a growing 
number of medical conditions.3 There is currently much 
confusion among health professionals and consumers as 
a result of conflicting information on the health benefits 
of vitamin D and dietary requirements. 
HISTORICAL PERSPECTIVE 
Rickets was first described in the mid 1600s and the condition became more common in the 18th century. 
By the 19th century it was epidemic in Europe, as more 
and more families moved from their farms to work in 
factories in the smoggy air of industrial cities. Very little 
progress was made during the 19th century to cure the 
condition and it took nearly three centuries before the 
anti-rachitic substance was identified as vitamin D in 
1922 (Table 1).4
Vitamin D is a generic term representing two che-
mical forms, vitamin D2 (ergocalciferol) and vitamin 
D3 (cholecalciferol), which differ only in the chemistry 
of the side chains. These differences do not affect the 
metabolism of vitamin D to any great extent, except 
that vitamin D2 may be metabolised more rapidly than 
vitamin D3. In general, they have comparable responses 
in the body.5 Vitamin D2, which can be produced by 
ultraviolet B irradiation of ergosterol (found naturally 
in yeast and sun-exposed mushrooms), was chemically 
characterised in 1932, with vitamin D3 following in 1936 
when researchers discovered that it was synthesised 
by ultraviolet irradiation of 7-dehydrocholesterol 
in the skin.6 An important development was that 
1,25-dihydroxyvitamin D [1,25(OH)2D], the active 
form of vitamin D, was reclassified as a hormone 
(more specifically a seco-hormone) responsible for the 
regulation of calcium metabolism.7 The next important 
landmark, in the 1970s, was the discovery of a vitamin D 
receptor that binds 1,25(OH)2D to the nucleus of cells 
– including cells that do not form part of the classical 
target tissues responsible for calcium maintenance.4 
Today there is evidence of biological responses in the 
immune system, pancreas and the cardiovascular, muscle 
and brain systems, in addition to the intestines and 
bones.
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6THE HANDLING OF VITAMIN D  
By THE BODy 
After entering the circulation, vitamin D2 and D3 are transported by vitamin D-binding protein to 
the liver, where they are hydroxylated by one or more 
cytochrome P450 vitamin D 25-hydroxylases (primarily 
CYP2R1) to 25-hydroxyvitamin D (25(OH)D), the most 
abundant and stable metabolite of vitamin D in the 
blood and generally accepted as the functional indicator 
of vitamin D status (Figure 1).9,10 It is the precursor to 
the only active form of vitamin D (1,25(OH)2D), which 
is synthesised mainly in the kidneys under the control 
of cytochrome P450 mono-oxygenase 25(OH)D 
1α-hydroxylase (CYP27B1).10 Then 1,25(OH)2D serves 
as a ligand that binds with high affinity to the steroid 
hormone nuclear receptor for 1,25(OH)2D (VDR)9,11 in 
cells to form a complex that influences the transcription 
and transrepression of multiple genes in target tissues. 
When the VDR is activated, it transcribes the gene 
for the P450 enzyme (24-hydroxylase or CYP24A1) 
that metabolises 1,25(OH)2D into inactive products 
as a feedback control mechanism. Another feedback 
mechanism limits the amount of 25(OH)D converted to 
1,25(OH)2D by 24-hydroxylase (CYP24A1).10,12  
The presence of VDRs in tissues that are not involved 
in mineral ion homeostasis led to the discovery of a 
number of other roles of vitamin D hormone.13 In its 
endocrine role, 1,25(OH)2D is released in the blood 
stream as a hormone with effects in other parts of the 
body. Its primary target is the intestinal mucosa, where 
it plays a role in the calcium transport system.9,11 Should 
the need arise to absorb more calcium, the synthesis 
of 1,25(OH)2D is tightly controlled with up-regulation 
via serum parathyroid hormone (PTH), while synthesis 
is down-regulated by fibroblast growth factor 23 
(FGF23) produced by the osteocytes.10,14 TThe VDR is 
also present in many other tissues of the body (Table 
2) where it may generate certain biological responses.15
Mid 1600 Rickets is first described
1827 French researcher reports cures among those given cod liver oil.
1919 Researcher cures children of rickets using artificially produced ultraviolet light.
1920s Researchers discover that irradiating certain foodstuffs with UV light renders those foods anti-rachitic.
1921 Researchers show that by simply exposing rachitic children to sunlight, they are able to cure them of 
the disease.
1922 Researcher destroys vitamin A in cod liver oil and calls the separate anti-rachitic substance that  
remains ‘vitamin D’.
1936 Researcher deduces chemical structure of vitamin D3 produced in the skin and identifies structure of 
7-dehydrocholesterol. 
1968 Researchers isolate an active vitamin D metabolite and identify it as 25-hydroxyvitamin D3, produced 
in the liver.
1969 Discovery of the nuclear receptor for 1,25(OH)2D3.
1970 Researchers discover the relationship of vitamin D to the body’s endocrine system and calcium  
regulation.
1971 Chemical/molecular structure of 1,25(OH)2D3 is identified and reclassified as a hormone controlling 
calcium metabolism.
1980 Researchers demonstrate that topical application of the vitamin D hormone is an effective treatment 
of psoriasis.
1980- Evidence that a vitamin D receptor is present in over 30 target tissues of man. 
1980- Discovery of 1,25(OH)2D-mediated rapid responses. 
1994 US Food and Drug Administration approves a vitamin D-based topical treatment for psoriasis.
2000 First X-ray structure of the VDR ligand-binding domain reported.
2004 Identification of an alternative ligand-binding pocket in the VDR.
Table 1: Selected timelines in the history of vitamin D4,6,8
7As opposed to the endocrine pathway, it is now known 
that. vitamin D also acts through an autocrine pathway. 
This means that the hormone binds to receptors on the 
cells locally where it is produced and affects the function 
of those cells. To date, 1α-hydroxylase has been identi-
fied in many extrarenal cells and tissues, including the 
prostate, breast, colon, lung, pancreatic β-cells, mono-
cytes and parathyroid cells, where it converts 25(OH)
D to 1,25(OH)2D intracellularly.11 The regulation of 
1α-hydroxylase at these sites is different from that in 
the kidney, as 1,25(OH)2D synthesis and degradation 
are under the control of local factors (e.g. cytokines and 
growth factors) aimed at the establishment of optimal 
levels of 1,25(OH)2D for cell-specific actions. This local 
pathway is dependent on adequate levels of circulating 
25(OH)D, which may explain the association of vitamin 
D deficiency with diseases such as cancer.13 These cells 
also produce vitamin D 24-hydroxylase (CYP24A1), 
which degrades excess 1,25(OH)2D intracellularly to 
pre vent excess accumulation.10 
System  Tissue and cell
Gastrointestinal Oesophagus, stomach, intestine
Musculoskeletal Osteoblasts, chondrocytes, striated muscle
Endocrine  Parathyroid, pancreatic ß cells, thyroid C cells
Renal  Tubules, juxtaglomerular apparatus (renin), podocytes
Cardiovascular Arterial smooth muscle cells, cardiac myocytes
Immune  T cells, B cells, bone marrow, thymus
Hepatic  Liver parenchymal cells
Reproductive  Testis, ovary, uterus
Respiratory  Lung alveolar cells
Epidermis  Keratinocytes, hair follicles
Central nervous system Brain neurons
Figure 1: Schematic overview of vitamin D metabolism and function5,10,13
Table 2: Distribution of vitamin D receptors in tissues15
8This new knowledge about the complex physiological 
roles of vitamin D has rekindled interest in the ‘sunshine 
vitamin’ and has led scientists to pursue many new 
applications for vitamin D, especially following reports 
of vitamin D deficiency in many parts of the world.
SOURCES OF VITAMIN D
It is no coincidence that vitamin D is called the ‘sunshine vitamin’. The best source of vitamin D is 
exposure of the skin to ultraviolet B (UVB) radiation 
with wavelengths of 290–315 nm, which leads to 
vitamin D3 being synthesised in the skin from cutaneous 
7-dehydrocholesterol (provitamin D3). UVB radiation 
leads to rearrangement of the double bonds and 
opening of the B ring of provitamin D3, resulting in a 
less rigid previtamin D3.16 Peak synthesis of vitamin D 
occurs at wavelengths of 295–297 nm, but this quality 
of light is found mainly in the tropical and subtropical 
climates and rarely in the arctic regions. Any excess 
vitamin D3 produced in the skin is converted to inactive 
products, which protect against toxicity due to excessive 
exposure to sunlight.11 Exposure of the body (in bathing 
suits) to UVB radiation until slight redness of the skin 
occurs will release 10 000–20 000 IU of vitamin D3 
into the circulation.17 The minimum amount of vitamin 
D required to maintain serum 25(OH)D in the optimal 
range is 1 000 IU.18 This translates into exposure of the 
arms and legs to sunlight for 5 to 30 minutes between 
10:00 and 15:00 in the spring, summer and fall, depending 
on skin pigmentation, latitude, season, clothing, the use 
of sunscreen and age.9 Usually, exposure twice a week 
is enough to produce sufficient amounts of vitamin D.
Natural food sources of vitamin D are scarce and it 
is difficult to achieve optimal serum levels of vitamin D 
by diet alone. The best food sources of vitamin D are 
fatty fish (such as salmon, tuna, herring, sardines and 
mackerel) and fish liver oils (cod liver oil), but small 
amounts are also found in butter, egg yolk and liver (Table 
3). Vitamin D in these foods is primarily in the form of 
vitamin D3.9 Natural vitamin D2 is found primarily in 
fungi, mushrooms and algae. Breast milk is a poor 
source of vitamin D, especially if the mother is vitamin 
D deficient. It is estimated that an average consumption 
of 750 mL/day of breast milk without exposure of the 
infant to sunlight will provide only 11–38 IU of vitamin D 
per day, which is much lower than the dietary reference 
intake.16,19 
Dietary supplements and foods fortified with vitamin 
D are important sources of dietary intake. Both vitamin 
D2 and vitamin D3 are suitable for supplements and food 
fortification.5,16 In most developing countries, however, 
the availability of foods fortified with vitamin D is not 
very reliable. Non-compliance of industry with vitamin 
D-fortification regulations20,21 may result in under- 
or over-fortification of foods, as has been reported 
in the USA in the nineties. Variations in fortification 
procedures such as storage of the vitamin preparation, 
method used for adding vitamin D and the timing at 
which point the vitamin D is added may further add to 
variation in the vitamin D content of fortified foods.21 
There is a limited number of food vehicles suitable for 
vitamin D fortification. These include margarine and 
dairy products,22 but orange juice and breakfast cereal 
have also been fortified.23 Policymakers should however 
take note of the outbreak of vitamin D intoxication in 
infants in the 1950s in Europe, which was believed to 
be the result of over-fortification of milk and which 
resulted in laws to stop the fortification of foods with 
vitamin D.24 Researchers now believe that this outbreak 
may have been caused by the presence of CYP24A1 
mutations, which have been linked with increased 
sensitivity to vitamin D. The presence of this mutation is 
a genetic risk factor for the development of symptomatic 
hypercalcaemia and it can be triggered by vitamin D 
prophylaxis in otherwise healthy infants.25
Vitamin D supplements are relatively cheap and 
widely available, either as multiple-vitamin preparations, 
combined with calcium, or as stand-alone vitamin D 
supplements. Doses commonly range from 400 IU to 
50 000 IU (primarily vitamin D3), and are available in 
various formulations such as tablets, capsules, liquid 
drops or chewables. Vitamin D3 has been shown to 
be more potent than vitamin D2 and to stay in the 
circulation longer than vitamin D2,26 but recent reports 
suggest that the two forms of vitamin D are equally 
effective in maintaining serum levels.18 There is however 
considerable variation in the way individuals respond to 
vitamin D supplementation and the only way to monitor 
efficacy and safety of intervention is to measure serum 
25(OH)D.9 
9Table 3: Examples of best sources of vitamin D in  
South Africa23,27
POTENTIAL CAUSES OF  
VITAMIN D DEFICIENCy 
The causes of vitamin D deficiency can be linked to decreased synthesis in the skin, decreased intake 
and certain medical conditions. The causes include the 
following:
l More time spent indoors 
l The use of sunscreen for protection against cancer 
(95% to 98% decrease in synthesis of vitamin D3 in 
the skin)28
l Amount and type of clothing (a fully clothed infant 
without a hat will need approximately two hours’ ex-
posure to UVB radiation per week compared to 30 
minutes per week for an infant wearing only a dia-
per,29 and women and children who wear traditional 
outfits that cover the face and body are at risk of 
vitamin D deficiency)30 
l Air pollution and overclouded sky31 
l Amount of melatonin in the skin (up to 99% decrease 
 
 in vitamin D3 synthesis due to ab- 
 sorption of UVB radiation)11
l  Higher latitudes (most vitamin D is 
formed at latitudes between 40˚N and 
40˚S) due to greater scatter and ab-
sorption of UVB radiation.32 In winter, 
above 37˚N the number of UVB pho-
tons reaching the earth is decreased 
by 80 to 100%.17 
l  Season (during winter fewer UVB 
photons strike the earth)33
l  Ageing (reduction in amount of 
7-dehydrocholes terol in the skin; el-
derly people produce up to 75% less 
vitamin D3)34
l  Amount of body fat (sequestration of 
vitamin D in adipose tissue)35,36 
l  Poor intake of vitamin D (includes 
natural food, fortified foods or vitamin 
D supplements, and exclusive breast-
feeding) 
l  Medical conditions interfering with the 
metabolism of vitamin D (e.g. kidney 
failure, liver disease and malabsorption 
syndromes) 
DIAGNOSIS OF VITAMIN D 
DEFICIENCy 
Serum 25(OH)D is the major circulating metabolite of vitamin D with a half-life of 10–19 days and only 
a fraction of 25(OH)D is converted to 1,25(OH)2D.16,17 
A systematic review of 36 randomised controlled trials 
(RCTs) and four before–after studies showed that serum 
25(OH)D is a robust and reliable biochemical marker 
of vitamin D status, responding to improved vitamin D 
status across heterogeneous population subgroups and 
irrespective of whether calcium is supplemented or not.37 
While total 25(OH)D level is used for the diagnosis and 
monitoring of vitamin D deficiency, it is suggested that 
25(OH)D2 and 25(OH)D3 fractions be used to monitor 
response to vitamin D2 or D3 supplementation.38 It is 
recommended that the measurement of serum levels of 
25(OH)D be reserved for individuals at risk of deficiency 
because of the following:38,39,40,41,42
l Renal and liver disease
l Osteomalacia, osteopenia and osteoporosis
Source Amount (IU)
Natural food 
Salmon, 100 g 520 
Sardines/pilchards, 100 g 280–320
Mackerel, 100 g 250
Tuna, 100 g 200–280 
Herring, 100 g 1 040
Cod liver oil, 1 teaspoon 400–500
Egg, 1 whole 158–168
Exposure to sunlight, UVB (0,5 MED)* 3 000 IU 
Fortified food 
Margarine, 1 teaspoon 10
Milk powder, 10 g ~35
Infant formula, 240 ml ~100
Breakfast cereal, 50 g 60–135
Supplements 
Vitamin D3 400–50 000 
* Approximately 0,5 MED of UVB radiation would be absorbed  
after 5 to 10 minutes of exposure of the arms and legs to direct  
sunlight, depending on the time of day, season, latitude and skin  
sensitivity.
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l Rickets
l Malabsorption syndromes
l Hypo- or hypercalcaemia/hyperphosphataemia
l Parathyroid disease
l Granulomatous disease
l Sarcoidosis
l Lymphoma
l Patients on medication that affect vitamin D metabo-
lism (glucocorticoids, antiseizure medications, anti-
retroviral drugs, antifungals, cholestyramine)
l Unexplained increased levels of serum alkaline phos-
phatase
l Patients taking high doses of vitamin D (> 2 000 IU 
daily) for more than six months or having symptoms 
of hypervitaminosis D 
l Pregnant and lactating women
l Older adults with a history of falls or non-traumatic 
fractures
l Malnourished patients (including obese children and 
adults)
l Limited sun exposure 
Serum 1,25(OH)2D, the active form of the vitamin with 
a half-life of only four hours, is not a good marker of 
vitamin D deficiency because the level of 1,25(OH)2D in 
the blood is usually normal or elevated in the presence 
of a vitamin D deficiency. This is because even subtle 
decreases in serum calcium due to vitamin D deficiency 
will lead to a corresponding increase in PTH, stimula-
tion of 1α-hydroxylase and conversion of 25(OH)D 
to 1,25(OH)2D.16 Measurement of serum 1,25(OH)2D 
should therefore be limited to cases suspected of having 
renal 1α-hydroxylase deficiency (i.e. chronic kidney dis-
ease), those with primary hyperparathyroidism, sarcoi-
dosis, oncogenic osteomalacia, vitamin D-resistant rick-
ets43 and hypercalcaemia with low levels of 25(OH)D.39 
It has been suggested that one should control for serum 
albumin levels when interpreting serum 25(OH)D, as 
the latter is transported in the blood bound to vitamin 
D-binding protein and albumin.44
Traditionally, serum 25(OH)D levels of 27,5 nmol/L 
and 30 nmol/L have been used as the cut-off point for 
adequacy in children and adults respectively, but in 
recent years, scientists suggested higher cut-off points 
of 50 nmol/L or above.45 These higher cut-off points are 
based on the effect of serum 25(OH)D levels on PTH 
secretion, reports on fracture prevention and intestinal 
calcium absorption rates.42 However, there is not yet 
agreement as to the optimal reference ranges that 
should be used to interpret serum 25(OH)D (Figure 2), 
and differences in reported prevalence rates for vitamin 
D deficiency can be expected due to different cut-off 
points being used.
Figure 2: Variation in cut-off points for serum 25(OH)D status in adults9,16,42,45,46  
Severe deficiency
Misra 2008
Mayo Clinic 2010
Agarwal 2011
EPGC 2011*
Institute of Medicine 2011
Deficiency Insufficiency Sufficiency
0 75 150 225 300
Serum 25(OH)D levels (nmol/L)
* Endocrine Practice Guidelines Committee 
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IS VITAMIN D DEFICIENCy STILL A 
PROBLEM TODAy? 
Until recently, it was assumed that most people are vitamin D sufficient. However, it seems that there 
has been a re-emergence of rickets in recent years, even 
in older children. It is especially dark-skinned infants who 
are exclusively breastfed beyond three to six months of 
age, infants whose mothers were vitamin D deficient 
during pregnancy16 and premature infants who are most 
at risk. Also, in countries such as Ethiopia47 and Tibet,48 
rickets has remained a public health problem. The Cen-
ters for Disease Control and Prevention reported a 50% 
drop in the percentage of vitamin D-sufficient adults in 
the USA from 1988–1994 to 2001–2004 and that more 
people are now severely deficient.49 In a recent report, the 
global prevalence of hypovitaminosis D varied between 
3% and 91%, but the interpretation of the data is hindered 
by the large variation in cut-off points used for vitamin D 
deficiency, which ranged from 12,5 nmol/L to 75 nmol/L.50
Data on vitamin D status for South Africa is almost 
non-existing. In vitro studies in Cape Town showed a 
marked seasonal variation in the production of vitamin 
D3, especially during the winter months of April through 
September. This is in contrast to Johannesburg, where in 
vitro formation changed little throughout the year.33 The 
first data on the vitamin D status of a cohort of healthy 
10-year-old children from Johannesburg were published 
in 2010. The prevalence of vitamin D deficiency was 7% 
and insufficiency was 19%.51 A study on 81 adolescents 
with alcohol use disorder and 81 matched light/non-
drinking adolescents in Cape Town showed that 
vitamin D deficiency was pre sent in 39% of the heavy-
drinking and 34% of the light/non-drinking adolescents 
(unpublished data).52 A study investigating the vitamin D 
status of mothers and their children from birth to three 
years of age in the Breede Valley, Worcester, is currently 
underway as part of the Community Nutrition Security 
Project (CNSP) of the HOPE Project of Stellenbosch 
University. This study will provide some insights into the 
vitamin D status of mothers and young children.
The reasons for the increased prevalence of vitamin D 
deficiency globally are not clear, but most likely include 
a combination of one or more of the following factors: 
1) the increase in the cut-off points used for the diagnosis 
of vitamin D deficiency, 
2) more time spent indoors, 
3) the use of sunscreen for cancer prevention when 
going outdoors, 
4) the global increase in the prevalence of obesity and 
5) increased air pollution in industrial areas.  
WHAT ABOUT VITAMIN D 
TOxICITy? 
Vitamin D used to be considered one of the potentially more dangerous vitamins that can lead to toxicity. 
Contrary to common belief, acute vitamin D overdose is 
usually the result of industrial accidents, and it has been 
suggested that vitamin D toxicity is unlikely to occur at 
intakes below 10 000 IU/day.53 The long-term effects of 
chronic exposure to medium to high doses of vitamin D 
have however not been sufficiently studied. 
It is known that vitamin D can cause hypercalcaemia 
in patients with parathyroid disease, granulomatous 
disease, sarcoidosis, lymphoma and kidney disease.40 
The Cohort Consortium Vitamin D Pooling Project of 
Rarer Cancers recently reported an increased risk of 
pancreatic cancer at serum 25(OH)D > 100 nmol/L.54 
In an ancillary randomised controlled substudy nested 
within the Women’s Health Initiative trial, coronary 
artery calcified plaque burden was not affected by 
moderate doses of calcium plus 400 IU vitamin D3.55 
However, a direct relationship between serum 25(OH)
D and the quantity of calcified atherosclerotic plaque 
in African-Americans was reported.56 The results of 
this study suggest that there are ethnical differences 
in the optimal range for serum 25(OH) and that there 
may be biologically mediated ethnic differences in the 
regulation of bone and vascular health. Long-term safety 
studies on the effect of vitamin D supplementation 
are required regarding the effect on atherosclerosis in 
African-Americans with vitamin D deficiency. Lastly, in 
the Women’s Health Initiative, the use of both calcium 
(1 000 mg/day) and vitamin D (400 IU) supplements 
was associated with a 17% increase in the risk of kidney 
stones over a period of seven years.57 The Food and 
Nutrition Board’s recommendation58 that serum 25(OH)
D levels > 125–150 nmol/L be avoided therefore needs 
to be verified by further studies. 
EVIDENCE OF THE BENEFICIAL 
EFFECT OF VITAMIN D 
SUPPLEMENTATION 
The best-known effect of vitamin D deficiency is a de-rangement in calcium, phosphorous and bone me-
tabolism. However, abnormalities in VDR activation and 
function are expected to have adverse effects on cellular 
function in several biological systems, including those 
not involved in mineral homeostasis.59 An association 
between vitamin D deficiency and many medical condi-
tions was suggested by observational studies. Systematic 
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reviews, for example, reported inverse relationships be-
tween serum 25(OH)D and colorectal ade noma incidence 
and recurrent adenomas,60 prostate cancer progression61 
and risk of breast cancer.62 The prospective study of the 
National Cancer Institute, on the other hand, did not find 
an association between serum 25(OH)D and total can-
cer mortality (with the exception of colorectal cancer 
mortality),63 and there was also no evidence of benefit 
from higher serum 25(OH)D (> 75 nmol/L) or increased 
risk at lower levels in the Cohort Consortium Vitamin D 
Pooling Project of Rarer Cancers.54 A systematic review 
of 13 observational studies showed that the association 
between vitamin D status and cardiovascular outcomes 
is uncertain.64 Other systematic reviews showed that 
children who received vitamin D supplementation in 
early childhood had a significantly lower risk of develop-
ing type 1 diabetes,65 and that there is an inverse rela-
tionship between serum 25(OH)D and the risk of active 
tuberculosis66 and HIV infection.67
The evidence from RCTs is summarised in Table 4. 
Several systematic reviews of RCTs failed to confirm the 
beneficial effect of vitamin D supplementation in patients 
suffering from cancer and cardiovascular disease. For 
falls and fractures, the results from systematic reviews 
are promising, yet inconsistent. In the case of diabetes, 
tuberculosis and influenza, no systematic reviews could 
be identified and the results from single RCTs are 
inconsistent. For most other conditions that have been 
linked to vitamin D, no RCTs could be identified. The 
differences in the results from RCTs may be explained 
in part by the large degree of heterogeneity in design 
between individual studies, especially in terms of
l	dosage of vitamin D used (varied between 200 IU and 
10 000 IU per day);
l	duration of follow-up (varied between one month and 
eight years); 
l	addition of calcium or not; and
l	failure to differentiate between vitamin D sufficiency 
and deficiency when analysing the results. 
The alternate hypothesis, that low levels of vitamin D 
may be the result of disease rather than its cause, is only 
now beginning to receive more attention as the results 
from RCTs are coming to the fore. In one study, for 
example, vitamin D deficiency developed in patients with 
peripheral arterial disease as a result of immobility and 
lack of exposure to sunlight.68 Even though it is possible 
that vitamin D deficiency may be the result of disease 
rather than its cause, its consequences need to be inves-
tigated, specifically whether vitamin D supplementation 
will be beneficial or cause more harm. 
A systematic review of 18 RCTs (57 311 participants) 
showed that daily vitamin D supplementation with 300–
2 000 IU was associated with a significant decrease in all-
cause mortality rates compared to controls.69 Evidence 
of the beneficial effects of vitamin D in individual ‘non-
classical’ medical conditions is however still unconvincing 
(Table 4). 
Table 4: Evidence of the beneficial role of vitamin D supplementation in selected ‘non-classical’ conditions 
Condition
Falls
Biological plausibility 
Muscle tissue expresses 
VDR70 that may promote 
synthesis of new muscle 
protein, therefore prevent-
ing falls.
Evidence from vitamin D intervention from RCTs 
Systematic reviews
•	 5	RCTs,	400–800	IU	D3/active	analogue,	800–1	200	mg	calcium,	2	months	
– 3 years follow-up, elderly71
 Significantly reduced falling by 22%
•	 8	RCTs	and	1	prospective	risk	factor	study,	300–800	IU	vitamin	D3,	18	
weeks – 5 years follow-up, vitamin D insufficient postmenopausal women72
 No significant effect on falls 
•	 13	RCTs,	vitamin	D3,	elderly73
 No significant change in group overall
 Significantly reduced number of falls in trials recruiting participants with 
lower vitamin D levels (only 260 participants)
 Adverse effects (hypercalcaemia, renal disease, gastrointestinal effects) 
reported in three trials 
•	 8	RCTs,	200–1	000	IU	vitamin	D2	and	D3/active	analogue,	800–1	200	mg	
calcium, 2–36 months follow-up, elderly74
 No significant effect at < 700 IU vitamin D
 Significant reduction in fall risk by 19% on 700–1 000 IU
 Serum 25(OH)D concentrations of 60 nmol/l or more resulted in a 23% 
fall reduction. However, the review was heavily criticised and when reana-
lysed the dose-response relationship disappeared.64
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Evidence from vitamin D intervention from RCTs
Systematic reviews
•	 6	and	8	RCTs,	postmenopausal	women76
 No significant effect on non-vertebral fractures
 Significant reduction in vertebral fractures 
•	 5	RCTs,	400–800	IU	vitamin	D3,	500–1	200	calcium,	 
2–5	years	follow-up,	elderly77
 400 IU not effective
 700–800 IU/d reduced risk of hip fracture significantly by 26%
•	 7	RCTs,	400–800	IU	vitamin	D3,	2–5	years	follow-up,	elderly	77
 700–800 IU/d reduced risk of non-vertebral fracture significantly by 23%  
(no significant benefit with 400 IU/d vitamin D)
•	 8	and	12	RCTs,	400–770	IU	vitamin	D3,	500–1	200	mg	calcium,	 
1–7	years	follow-up,	elderly78
 No significant effect on hip fractures
 Significant at the higher dose
 Significant reduction in non-vertebral fractures, at least 20% if > 400 IU/d 
vitamin D
•	 8	RCTs	and	1	prospective	risk	factor	study,	300–800	IU	vitamin	D3,	
18	weeks	–	5	years	follow-up,	vitamin	D	insufficient	 
postmenopausal	women72
 No significant effect on fractures
•	 7	RCTs,	400–800	IU	vitamin	D2/D3,	0–1	000	mg	calcium,	 
18–85	months	+	follow-up79 
 Vitamin D alone not effective
 Vitamin D with calcium reduced overall risk of hip and overall fracture signifi-
cantly
Systematic reviews
•	 16	RCTs,	400–3	700	IU	vitamin	D2/9	000	IU	D3,	500–1	000	mg	 
calcium,	2–6	months	follow-up,	adults	>	50	years80
 In only 7 RCTs, a beneficial effect was documented for muscle strength of the 
lower legs, body sway, physical performance (no meta-analysis) 
•	 17	RCTs,	vitamin	D,	adults81 
 No effect on grip strength, proximal lower limb strength, if serum 25(OH)D > 
25 nmol/L
 Large effect on hip muscle strength in 2 studies where serum 25(OH)D < 25 
nmol/L
Systematic reviews
•	 2	RCTs,	830–1	000	IU/d	vitamin	D3,	1	400–1	500	mg	calcium,	 
4–5	years	follow-up,	postmenopausal	women,	elderly83 
 No significant effect on cancer risk or cancer mortality 
 
Single RCTs 
•	 400	IU	vitamin	D,	1	000	mg	calcium,	8	years	follow-up,	postmeno-
pausal	women	(The	Women’s	Health	Initiative)
 No significant effect on the risk of colorectal cancer84 
 No effect on the risk of breast cancer 85 
Biological  
plausibility
 
Decrease in serum calcium 
due to vitamin D deficiency 
will cause secondary hyper-
parathyroidism, increased 
bone resorption, decreased 
bone mineral density and 
increased risk of fractures.75
See falls
Acts via the autocrine 
pathway, the immune system 
and epithelial cell types 
in the breast, colon, lung, 
skin and prostate,9 where 
1a-hydroxylases convert 
25(OH)D to 1,25(OH)2D 
intracellularly. The 
1,25(OH)2D is involved in 
inhibition of cell proliferation 
and cell adhesion, induction of 
apoptosis, G1 phase cell-cycle 
arrest, and promotion of cell 
differentiation, inhibition of 
angiogenesis, alteration of 
growth factors and inhibition 
of metastasis.82
Fractures
Muscle 
strength
Cancer
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Evidence from vitamin D intervention from RCTs
Systematic reviews
•	 11	RCTs,	vitamin	D2/D3/active	analogue,	adults 86
 No significant reduction in systolic BP
 Small significant reduction in diastolic BP 
•	 8	RCTs,	1	000	IU	vitamin	D,	calcium,	adults87  
 No significant effect on cardiovascular risk
•	 10	RCTs,	1	000	IU	vitamin	D,	calcium,	healthy	adults64
 No significant effect on BP
No systematic reviews were identified
Single RCTs
•	 300	000	IU	vitamin	D3	at	baseline,	4	weeks	follow-up,	
type	2	diabetes	mellitus	(adults)88 
 No improvement in glucose tolerance, insulin secretion or insulin 
sensitivity 
•	 500	IU	vitamin	D,	150–250	mg	calcium,	12	weeks	follow-
up,	type	2	diabetes	mellitus	(adults)89 
 Significant improvement of insulin secretion and insulin sensitivity 
as well as decreased waist circumference and BMI
•	 2	000	IU	vitamin	D,	16	weeks	follow-up,	type	2	diabetes	
mellitus (adults)90	
 Significant improvement in pancreatic β-cell function
•	 4	000	IU	vitamin	D3,	6	months	follow-up,	type	2	diabetes	
mellitus (adults)91 
 Significant improvements in insulin sensitivity and insulin resistance  
in subjects who were insulin resistant with serum 25(OH)D < 50 
nmol/l; insulin resistance most improved with serum 25(OH)D > 
80 nmol/l 
 Significant reduction in fasting insulin
 No effect on C-peptide, lipid profile, high-sensitivity C-reactive 
protein; optimal serum 25(OH)D to reduce insulin resistance was 
80–119 nmol/l 
No systematic reviews were identified 
Single RCTs
•	 1	200	IU	vitamin	D,	4	months	follow-up,	children95
 Influenza occurred significantly less often in the vitamin D than in 
the placebo group between days 31 and 60 only 
•	 2	000	IU	vitamin	D3,	12	weeks	follow-up,	adults97 
 No benefit
Evidence from vitamin D intervention from RCTs
No systematic reviews were identified 
Single RCTs
•	 100	000	IU	vitamin	D3	at	inclusion,	5	and	8	months,	 
1	year	follow-up,	tuberculosis	patients94 
 Vitamin D does not improve clinical outcome among patients with 
TB and the trial showed no overall effect on mortality in patients 
with TB
•	 Four	doses	of	2–5	mg	vitamin	D3,	42	days	follow-up,	 
pulmonary tuberculosis patients95
 No effect on sputum conversion in the group as a whole 
 Significantly expedited sputum culture conversion in participants 
with the tt genotype of the TaqI vitamin D receptor  
polymorphism
Biological  
plausibility 
Acts via the VDR, which is ex-
pressed in vascular smooth muscle 
cells, renal juxtaglomerular cells 
and cardiac myocytes. Vitamin D 
deficiency may be associated with 
alterations in the structural compo-
nents of cardiac myocytes and/or 
the neurohormonal cascade as well 
as altered cardiac contractility. It is 
hypothesised that injured myocar-
dium contains ineffective  
1--hydroxylase activity, re-
sulting in sub-optimal levels of 
1,25(OH)2D.45 
Acts via VDRs in pancreatic β-cells, 
may augment insulin secretion and 
insulin sensitivity.5
May be related to seasonal  
oscillation of serum vitamin D 
concentrations and effect on  
innate immunity.96
Biological  
plausibility 
Increased cellular immunity by  
acting as an intermediate in the 
production of antimicrobial 
peptides such as cathelicidin by 
monocyte-macrophages,9 which 
allow the immune system to rec-
ognise and respond to microbes,92 
including mycobacterium  
tuberculosis.93 
Cardio- 
vascular 
Diabetes
Influenza
Tuber-
culosis
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PREVENTION OF VITAMIN D 
DEFICIENCy 
In November 2010, the Institute of Medicine (IOM) revised the recommendations for daily intake of 
vitamin D (Table 5),45 pointing out that these are the 
levels of intake recommended in the absence of adequate 
exposure to sunlight. The IOM warns that very high 
levels of vitamin D (more than 10 000 IUs per day) may 
cause kidney and tissue damage, challenging the concept 
that ‘more is better’. 
The IOM recommendations have been criticised as 
being overly cautious and in 2011 the Endocrine Practice 
Guidelines Committee released a new set of even higher 
recommendations (Table 5),42 based on the observation 
that it requires at least 1 000 IU/d of vitamin D to 
raise the blood levels of 25(OH)D consistently above 
75 nmol/L (the proposed cut-off point for sufficiency). 
In adults and in pregnant women, this amount will 
be 1 500–2 000 IU/d of vitamin D. Furthermore, it is 
suggested that obese children and adults and those 
individuals treated with anticonvulsant medications, 
gluco corticoids, antifungals such as ketoconazole, and 
antiretroviral drugs will require at least two to three 
times the amount of vitamin D recommended for their 
respective age group. The Committee acknowledged 
that these recommendations are often based on lower-
quality evidence (expert opinion, consensus, inference 
from basic science experiments and observational stu-
dies) and advises that the guidelines be seen as sugges-
tions rather than recommendations. The Committee’s 
guideline for an UL of up to 10 000 IU in adults is 
based on the results of a dose-ranging study in men, 
where 10 000 IU/d of vitamin D did not change urinary 
calcium excretion or serum calcium over a period 
of five months.98 It is recommended that blood and 
urinary calcium levels be monitored in patients who 
have chronic granuloma-forming disorders (sarcoidosis, 
tuberculosis) and chronic fungal infections and patients 
with lymphoma who have activated macrophages that 
produce 1,25(OH)2D in an unregulated fashion. These 
patients can have increased calcium absorption from the 
gut and mobilisation from bone.  
Table 5: Recommended daily vitamin D intakes
                                           Institute of Medicine45                                   Endocrine Practice   
                             Guidelines Committee42
Life stage group AI EAR RDA ULa Daily requirement ULa
0–6	months 400 IU   1 000 IU 400–1 000 IU 2 000 IU
6–12	months 400 IU   1 500 IU 400–1 000 IU 2 000 IU
1–3	years  400 IU 600 IU 2 500 IU 600–1 000 IU 4 000 IU
4–8	years  400 IU 600 IU 3 000 IU 600–1 000 IU 4 000 IU
9–13	years  400 IU 600 IU 4 000 IU 600–1 000 IU 4 000 IU
14–18	years  400 IU 600 IU 4 000 IU 600–1 000 IU 4 000 IU
19–70	years  400 IU 600 IU 4 000 IU 1 500–2 000 IU 10 000 IU
>70	years  400 IU 800 IU 4 000 IU 1 500–2 000 IU 10 000 IU
14–18	years	pregnancy  400 IU 600 IU 4 000 IU 600–1 000 IU 4 000 IU
19–50	years	pregnancy  400 IU 600 IU 4 000 IU 1 500–2 000 IU 10 000 IU
14–18	years	lactation  400 IU 600 IU 4 000 IU 600–1 000 IUb 4 000 IU
19–50	years	lactation  400 IU 600 IU 4 000 IU 1 500–2 000 IUb 10 000 IU
AI:   Adequate intake; EAR: estimated average requirement; RDA: Recommended dietary allowance; UL: tolerable upper intake level
a     Upper limit should not be exceeded without medical supervision.
b     Mother’s requirement, 4 000–6 000 IU/d (mother’s intake for infant’s requirement if infant is not receiving 400 IU/d).
The American Academy of Pediatrics99 provided the 
following supplementation guidelines for the prevention 
of vitamin D deficiency in infants and children:
l	All breastfed infants as well as non-breastfed infants 
and children ingesting less than 1 L of vitamin D-forti-
fied milk per day (400 IU of vitamin D within days of 
birth). This should continue throughout childhood.
l	Infants and children who are already vitamin D in-
sufficient or deficient (1 000 IU/day of vitamin D for 
infants < 1 month old, 1 000 to 5 000 IU/day for chil-
dren 1–12 months old and > 5 000 IU/day for children 
> 12 months old). This should be followed by 400 
IU per day of vitamin D supplementation to maintain 
serum 25(OH)D >50 nmol/L. 
l	Simultaneous calcium supplementation to prevent hy-
pocalcaemia secondary to decreased demineralisation 
of bone or increased remineralisation. 
In general, a healthful approach to prevent vitamin D 
deficiency may include the following:
l	Light to moderate sun exposure in line with cancer-
prevention guidelines
l	Adequate intake of good food sources of vitamin D, 
aiming for the recommended intakes in all groups 
l	Supplementation of vitamin D in safe amounts in 
individuals identified as being deficient, insufficient or 
at risk of deficiency. Currently there is no convincing 
evidence that supplementation beyond recommended 
intake is needed for non-calcaemic benefits.
l	If high-dose supplementation is required, caution 
should be exercised and serum levels of 25(OH)D 
should be monitored to ensure safety
THE WAy FORWARD
In South Africa there is no national data on the vitamin D status of the population, and research on particularly 
the groups at risk of vitamin D deficiency should be a 
priority. Ideally, this should form part of the research 
agenda of the South African National Health and 
Nutrition Examination Survey, but due to the geographic 
differences between the provinces, this research could 
also be undertaken at provincial level in areas where 
cutaneous synthesis via UVB radiation is expected to 
be low, such as in the Western Cape. Such data would 
be required for the development of policy regarding the 
need for vitamin D supplementation in at-risk groups, 
including exclusively breastfed infants.  
Although food fortification can reach a much larger 
target group of the population than supplementation, 
mandatory food fortification with vitamin D cannot be 
justified for South Africa at this point in time. It is vitally 
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